TY - JOUR
T1 - A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and Probationers
AU - Coviello, Donna M.
AU - Cornish, James W.
AU - Lynch, Kevin G.
AU - Boney, Tamara Y.
AU - Clark, Cynthia A.
AU - Lee, Joshua D.
AU - Friedmann, Peter D.
AU - Nunes, Edward V.
AU - Kinlock, Timothy W.
AU - Gordon, Michael S.
AU - Schwartz, Robert P.
AU - Nuwayser, Elie S.
AU - O'Brien, Charles P.
N1 - Funding Information:
ABSTRACT. A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up Donna M. Coviello, James W. Cornish, Kevin G. Lynch, Tamara Y. Boney, Cynthia A. Clark, and Charles P. O’Brien are affiliated with the University of Pennsylvania, Philadelphia, Pennsylvania, USA. James W. Cornish and Charles P. O’Brien are also affiliated with the Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA. Joshua D. Lee is affiliated with New York University/Bellevue Hospital, New York, New York, USA. Peter D. Friedmann is affiliated with the Veterans Affairs Medical Center, Rhode Island Hospital, Providence, Rhode Island, USA; and Brown University, Providence, Rhode Island, USA. Edward V. Nunes is affiliated with Columbia University, New York, New York, USA. Timothy W. Kinlock, Michael S. Gordon, and Robert P. Schwartz are affiliated with Friends Research Institute, Baltimore, Maryland, USA. Timothy W. Kinlock is also affiliated with the University of Baltimore, Baltimore, Maryland, USA. Elie S. Nuwayser is affiliated with Biotek, Inc., Woburn, Massachusetts, USA. Address correspondence to: Donna M. Coviello, PhD, Treatment Research Center, 3440 Market Street, Suite 370, Philadelphia, PA 19104, USA (E-mail: coviello [email protected]). The study was supported by grants from the National Institute on Drug Abuse (R01-DA-012268-05) and the Dana foundation.
PY - 2012/1/1
Y1 - 2012/1/1
N2 - A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.
AB - A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.
KW - Depotrex
KW - Extended-release naltrexone
KW - addiction pharmacotherapy
KW - heroin
KW - offenders
KW - opioid dependence
UR - http://www.scopus.com/inward/record.url?scp=84856945762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856945762&partnerID=8YFLogxK
U2 - 10.1080/08897077.2011.609438
DO - 10.1080/08897077.2011.609438
M3 - Article
C2 - 22263713
AN - SCOPUS:84856945762
SN - 0889-7077
VL - 33
SP - 48
EP - 59
JO - Substance Abuse
JF - Substance Abuse
IS - 1
ER -